A cross-sectional study to determine protective duration of primary and booster doses of BNT162b2 and ChAdOx1 COVID-19 vaccine in Saudi Arabia
Latest Information Update: 02 Sep 2022
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 02 Sep 2022 New trial record
- 30 Aug 2022 Results published in the Clinical Drug Investigation